載入...
Tertiary Care Experience of Sorafenib in the Treatment of Progressive Radioiodine-Refractory Differentiated Thyroid Carcinoma: A Korean Multicenter Study
Background: Sorafenib, a multi-kinase inhibitor, is approved for the treatment of patients with radioactive iodine (RAI)-refractory differentiated thyroid cancer (DTC). This study evaluated the efficacy and safety of sorafenib in real-world clinical practice and compared the results to those of the...
Na minha lista:
| 發表在: | Thyroid |
|---|---|
| Main Authors: | , , , , , , , , , |
| 格式: | Artigo |
| 語言: | Inglês |
| 出版: |
Mary Ann Liebert, Inc., publishers
2018
|
| 主題: | |
| 在線閱讀: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6225595/ https://ncbi.nlm.nih.gov/pubmed/29350109 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1089/thy.2017.0356 |
| 標簽: |
添加標簽
沒有標簽, 成為第一個標記此記錄!
|